Drug Profile

Bimatoprost analogue - SpyGlass Pharma

Alternative Names: Second generation bimatoprost

Latest Information Update: 11 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SpyGlass Pharma
Class Amides; Antiglaucomas; Eye disorder therapies; Lipids; Prostaglandins; Small molecules
Mechanism of Action Prostaglandin F2alpha receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Glaucoma

Most Recent Events

11 Jul 2025 SpyGlass Pharma pipeline, July 2025- Early research line forwarded to preclinical and KDM, devT, HE and Intro updated
11 Jul 2025 Preclinical trials in Glaucoma in USA (Intraocular), prior to July 2025 (SpyGlass Pharma pipeline, July 2025)
21 Oct 2022 Early research in Glaucoma in USA (Intraocular) prior to October 2022 (SpyGlass Pharma website, October 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com